⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
ALLO News
Allogene Therapeutics, Inc. Common Stock
CAR T-cell Therapy for NHL Clinical Trial Landscape Expands: Over 70 Companies Advancing Next-Generation Therapies | DelveInsight
globenewswire.com
NVS
ALLO
LEGN
CBIO
MBIO
CRSP
INCY
IMPP
SANA
VOR
CARG
AUTL
ARCL
LYEL
PRE
BEAM
CART
TAK
AZN
MRK
BMY
GEN
DGX
GMAB
ABBV
RLGT
CRGO
JNJ
GILD
JAZZ
SYBX
CASI
ATRA
SHEN
BIIB
VREX
Form 8-K
sec.gov
ALLO
Allogene Therapeutics Announces Retirement of Chief Financial Officer Geoffrey Parker
globenewswire.com
ALLO
Allogene Therapeutics Announces Participation in September Investor Conference
globenewswire.com
ALLO
Global CD70-Targeting Therapies Market Report 2026 - Highlights Clinical Innovation, Pipeline Trends and Commercial Opportunities
globenewswire.com
ALLO
CRSP
JNJ
PFE
ADCT
REGN
MRNA
BMY
GILD
AMGN
BIIB
AZN
NVS
LLY
ABBV
Form 8-K
sec.gov
ALLO
Allogene Therapeutics Reports Second Quarter 2026 Financial Results and Business Update
globenewswire.com
ALLO
Allogene Therapeutics to Report Second Quarter 2026 Financial Results and Provide Business Update
globenewswire.com
ALLO
Allogene Therapeutics Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for Cemacabtagene Ansegedleucel (Cema-Cel) as First-Line Consolidation Therapy for Large B-Cell Lymphoma
globenewswire.com
ALLO
Allogene Therapeutics Announces Journal of Clinical Oncology Publication of Phase 1 Results of ALLO-316 Highlighting First Durable Remissions Following Allogeneic CAR T for Treatment of Metastatic Solid Tumors
globenewswire.com
ALLO